Latest Insider Transactions at Data Knights Acquisition Corp. (DKDCW)
This section provides a real-time view of insider transactions for Data Knights Acquisition Corp. (DKDCW). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Data Knights Acquisition Corp. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Data Knights Acquisition Corp.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 26
2025
|
Kenneth Alleyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,219
+50.0%
|
-
|
|
Nov 26
2025
|
Eric Casaburi Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+28.94%
|
-
|
|
Nov 26
2025
|
Andrew B Zeinfeld Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+10.55%
|
-
|
|
Nov 26
2025
|
Jair Clarke Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+24.53%
|
-
|
|
Nov 26
2025
|
Thomas Kosasa Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+0.28%
|
-
|
|
Nov 26
2025
|
Sherry Coonse Mc Craw Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+44.4%
|
-
|
|
Nov 26
2025
|
Aaron Green Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+2.28%
|
-
|
|
Nov 26
2025
|
Robert Lawrence Golden Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+7.59%
|
-
|
|
Nov 26
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+0.61%
|
-
|
|
Nov 24
2025
|
Aaron Green Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+34.66%
|
-
|
|
Nov 24
2025
|
Robert Lawrence Golden Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
333,333
+22.6%
|
-
|
|
Nov 24
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+2.67%
|
-
|
|
Nov 18
2025
|
Aaron Green Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
61,555
-3.3%
|
$61,555
$1.2 P/Share
|
|
Oct 22
2025
|
Aaron Green Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
64,767
-3.36%
|
$129,534
$2.23 P/Share
|
|
Oct 15
2025
|
Eric Casaburi Director |
BUY
Open market or private purchase
|
Direct |
10,000
+13.25%
|
$30,000
$3.05 P/Share
|
|
Sep 25
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,250
+0.02%
|
$1,250
$1.03 P/Share
|
|
Sep 24
2025
|
Thomas Kosasa Director |
BUY
Open market or private purchase
|
Direct |
6,000
+0.04%
|
$0
$0.93 P/Share
|
|
Sep 24
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
17,200
+0.24%
|
$17,200
$1.02 P/Share
|
|
Sep 23
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
5,700
+0.08%
|
$0
$0.93 P/Share
|
|
Sep 22
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
400
+0.01%
|
$0
$0.95 P/Share
|
|
Sep 19
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,250
+0.02%
|
$0
$0.89 P/Share
|
|
Sep 18
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
700
+0.01%
|
$0
$0.91 P/Share
|
|
Sep 05
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,100
+0.03%
|
$0
$0.86 P/Share
|
|
Sep 04
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
11,810
+0.17%
|
$0
$0.87 P/Share
|
|
Sep 03
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
11,670
+0.17%
|
$0
$0.81 P/Share
|
|
Sep 02
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
24,319
+0.34%
|
$0
$0.85 P/Share
|
|
Aug 29
2025
|
Thomas Kosasa Director |
BUY
Open market or private purchase
|
Direct |
581,395
+3.56%
|
$0
$0.86 P/Share
|
|
Aug 29
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,890
+0.16%
|
$0
$0.82 P/Share
|
|
Aug 28
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
17,000
+0.24%
|
$0
$0.8 P/Share
|
|
Aug 27
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
21,374
+0.31%
|
$0
$0.69 P/Share
|
|
Aug 26
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
173,350
+2.43%
|
$0
$0.69 P/Share
|
|
Aug 25
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
13,300
+0.2%
|
$0
$0.75 P/Share
|
|
Aug 21
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+0.22%
|
$0
$0.77 P/Share
|
|
Aug 19
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
16,500
+0.24%
|
$0
$0.77 P/Share
|
|
Jun 20
2025
|
Thomas Kosasa Director |
BUY
Open market or private purchase
|
Direct |
1,190,476
+7.28%
|
$0
$0.42 P/Share
|
|
Jun 20
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,666,666
+19.83%
|
$0
$0.42 P/Share
|
|
Jun 19
2025
|
Thomas Kosasa Director |
BUY
Conversion of derivative security
|
Direct |
4,988,440
+16.54%
|
$0
$0.73 P/Share
|
|
Jun 19
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Conversion of derivative security
|
Direct |
1,828,279
+26.5%
|
$0
$0.71 P/Share
|
|
Jun 17
2025
|
Thomas Kosasa Director |
BUY
Conversion of derivative security
|
Direct |
493,056
+5.21%
|
$493,056
$1.14 P/Share
|
|
Jun 17
2025
|
Aaron Green Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
240,425
+21.36%
|
$240,425
$1.14 P/Share
|
|
Jun 17
2025
|
Jeffrey Yu Chief Medical Officer |
BUY
Conversion of derivative security
|
Direct |
479,270
+12.88%
|
$479,270
$1.14 P/Share
|
|
Jun 16
2025
|
Thomas Kosasa Director |
BUY
Open market or private purchase
|
Direct |
55,000
+0.64%
|
$0
$0.38 P/Share
|
|
Apr 21
2025
|
Thomas Kosasa Director |
BUY
Open market or private purchase
|
Direct |
47,000
+0.55%
|
$0
$0.49 P/Share
|
|
Jan 31
2025
|
Robert Lawrence Golden Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,272
+12.52%
|
-
|
|
Jan 01
2025
|
Andrew B Zeinfeld Director |
BUY
Grant, award, or other acquisition
|
Direct |
82,143
+19.62%
|
-
|
|
Jan 01
2025
|
Jair Clarke Director |
BUY
Grant, award, or other acquisition
|
Direct |
82,143
+46.77%
|
-
|
|
Dec 18
2024
|
Jeffrey Yu Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
100
+0.0%
|
$0
$0.99 P/Share
|
|
Nov 20
2024
|
Eric Casaburi Director |
BUY
Open market or private purchase
|
Direct |
1,300
+2.29%
|
$0
$0.87 P/Share
|
|
Nov 12
2024
|
Eric Casaburi Director |
BUY
Open market or private purchase
|
Direct |
500
+0.91%
|
$0
$0.85 P/Share
|
|
Oct 01
2024
|
Jair Clarke Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,342
+50.0%
|
-
|